Treatment of fibrocystic breast disease – a way to prevent breast cancer

Authors

  • И. И. Смоланка Oncology Institute of the NAMS of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.22.65-69

Keywords:

fibrocystic breast disease, breast cancer, Epigalin®, Tazalok™

Abstract

The issues of classification, etiology, pathogenesis, clinical presentation, diagnosis and treatment of fibrocystic breast disease in the context of the prevention of breast cancer are present in this article.

Treatment of most cases of fibrocystic breast disease is carried by conservative methods. The most frequently used pathogenetic grounded herbal medicine, hormone therapy, anti-hormones, vitamins, enzyme therapy. Nodal forms of fibrocystic breast disease are subject to surgical treatment.

An individual program of screening is developed for women, depending on the degree of breast cancer risk. Studies in recent years allow us to consider the use of such drug as Epigalin® for a prophylactic measure in high-risk women

Author Biography

И. И. Смоланка, Oncology Institute of the NAMS of Ukraine

MD, Professor, Head of the Breast Pathology Department

References

  1. Smolanka, I.I., Skliar, S.Y. Ways of improving the efficiency of complex treatment of patients with breast cancer. Kyiv. Steel (2007): 191 p.
  2. Putyrskiy, L.A. Breast Cancer: study guide. Minsk. High School (1998): 95 p.
  3. Grio, R., Cellura, A., Geranio, R., et al. “Clinical efficacy of tamoxifen in the treatment of premenstrual mastodynia.” Minerva Ginecologica, 3(1998) (Vol. 50): 101–103.
  4. Neustadt, E.L., Vorobyeva, O.A. Pathology of breast: study guide. St. Petersburg. Foliant (2003): 207 p.
  5. Kosei, N.V. “Phytotherapy in the treatment of dishormonal benign breast diseases in women with uterine leiomyoma.” Reproductive women health, 4(38) (2008): 171–173.
  6. Tatarchuk, T.F., Kosei, N.V., Tutchenko, T.N. “Treatment of stress-induced luteal phase deficiency.” Reproductive Gynecology, 2(2012): 34–41.
  7. Strnad, P., Zavadil, M., et al. “The importance of hormone receptors in benign breast diseases.” Ceska Gynekol, 1(1998) (Vol. 63): 29–38.
  8. Tatarchuk, T.F., Solskyi, Y.P. Endocrine gynecology (clinical essays). Part 1. Kyiv (2003).
  9. Reznikov, O.G., Tarasenko, L.V. Pharmacology and drug toxicology, 6(25) (2011): 30–34.
  10. Grishchenko, O.V., Abdullaiev, R.Y., Dolenko, O.V., Pak, S.A. “Ultrasound diagnosis and comprehensive treatment of diffuse fibrocystic breast in women of reproductive age.” Women's Health, 9(45) (2009): 134.
  11. Tovstanovskaia, V.A., Vorobei-Vikhovskaia, V.N., Sakharova, I.A. “The new word in non-hormonal therapy fibrocystic breast mastopathy.” Women's Health, 1(47) (2010): 63–66.
  12. Ashrafyan, L.A., Kiselev, V.I., Ovchinnikova, O.A., Antonova, I.B. “Metabolites of estrogen in breast cancer patients and possible correction.” Materials of the IX Russian school “Fundamentals of Clinical Mammalogy”. Moscow (2008).

Downloads

Published

2015-04-14

How to Cite

Смоланка, И. И. (2015). Treatment of fibrocystic breast disease – a way to prevent breast cancer. REPRODUCTIVE ENDOCRINOLOGY, (22), 65–69. https://doi.org/10.18370/2309-4117.2015.22.65-69

Issue

No. 22 (2015)

Section

Tumors and pretumoral pathology

License

Copyright (c) 2015 И. И. Смоланка

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.